{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:02Z","timestamp":1790746802323,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute myeloid leukemia (AML) remains a formidable blood cancer, despite recent advances in treatment. A significant challenge persists in improving patient outcomes, particularly in addressing relapse and treatment resistance. Identifying new therapeutic targets is critical for advancing AML therapy. C-type lectin-like molecule-1 (CLL-1) has emerged as a promising therapeutic target in AML. This cell surface receptor is highly expressed on AML blasts and demonstrates stable expression throughout disease progression. CLL-1\u2019s consistent presence makes it an ideal candidate for monitoring minimal residual disease (MRD), which is a critical indicator for predicting relapse. Beyond its utility as a diagnostic marker, CLL-1 offers exciting potential in the development of immunotherapies. Emerging strategies, such as CAR-T-cell therapy and antibody-drug conjugates (ADCs), are being investigated to leverage the immune system against CLL-1-expressing AML cells. This review examines the structure, function, and expression patterns of CLL-1 in AML and other hematologic malignancies, providing insights into its role in disease pathogenesis and treatment potential. Exploring CLL-1 as a target for diagnosis, MRD monitoring, and immunotherapy opens new avenues for AML treatment. A deeper understanding of its relationship with AML pathogenesis will aid in the development of targeted therapies, offering hope for improved patient outcomes in the future.<\/jats:p>","DOI":"10.1186\/s40364-025-00738-6","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:18:56Z","timestamp":1739366336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Unveiling the potential of CLL-1: a promising target for AML therapy"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5998-1722","authenticated-orcid":false,"given":"Sara","family":"Zehtabcheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh Rahmani","family":"Seraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safedin H.","family":"Beqaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0436-5109","authenticated-orcid":false,"given":"Shamim","family":"Tayefeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4884-5218","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-6657","authenticated-orcid":false,"given":"Mojtaba","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"1","key":"738_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"738_CR2","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.","journal-title":"Blood Cancer J"},{"key":"738_CR3","doi-asserted-by":"crossref","unstructured":"Teixeira A et al. Current and emerging techniques for diagnosis and MRD detection in AML: a Comprehensive Narrative Review. Cancers (Basel), 2023. 15(5).","DOI":"10.3390\/cancers15051362"},{"issue":"9","key":"738_CR4","first-page":"2289","volume":"108","author":"J Senapati","year":"2023","unstructured":"Senapati J, Kadia TM, Ravandi F. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica. 2023;108(9):2289\u2013304.","journal-title":"Haematologica"},{"issue":"5","key":"738_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, L\u00f6wenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487\u201394.","journal-title":"J Clin Oncol"},{"issue":"2","key":"738_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.","journal-title":"Blood Cancer J"},{"issue":"3","key":"738_CR7","doi-asserted-by":"publisher","first-page":"e438662","DOI":"10.1200\/EDBK_438662","volume":"44","author":"Y Abaza","year":"2024","unstructured":"Abaza Y, McMahon C, Garcia JS. Advancements and challenges in the treatment of AML. Am Soc Clin Oncol Educ Book. 2024;44(3):e438662.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"738_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108(2):353\u201366.","journal-title":"Haematologica"},{"key":"738_CR9","doi-asserted-by":"crossref","unstructured":"Heuser M et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021. 138(26): pp. 2753\u20132767.","DOI":"10.1182\/blood.2021013626"},{"issue":"15","key":"738_CR10","doi-asserted-by":"publisher","first-page":"14792","DOI":"10.1074\/jbc.M313127200","volume":"279","author":"AS Marshall","year":"2004","unstructured":"Marshall AS, et al. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem. 2004;279(15):14792\u2013802.","journal-title":"J Biol Chem"},{"key":"738_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26\u201333.","journal-title":"Blood Rev"},{"issue":"3","key":"738_CR12","doi-asserted-by":"publisher","first-page":"105765","DOI":"10.1016\/j.jbc.2024.105765","volume":"300","author":"H Tang","year":"2024","unstructured":"Tang H, et al. Mechanistic insights into the C-type lectin receptor CLEC12A-mediated immune recognition of monosodium urate crystal. J Biol Chem. 2024;300(3):105765.","journal-title":"J Biol Chem"},{"key":"738_CR13","first-page":"39","volume-title":"Clinical immunology (Fifth Edition)","author":"DR McDonald","year":"2019","unstructured":"McDonald DR, Levy O. 3 - innate immunity. In: Rich RR, et al. editors. Clinical immunology (Fifth Edition). London: Elsevier; 2019. pp. 39\u2013e531."},{"key":"738_CR14","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/gene\/160364. 2024; Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/160364"},{"key":"738_CR15","first-page":"117","volume":"429","author":"C Del Fresno","year":"2020","unstructured":"Del Fresno C, Cueto FJ, Sancho D. Sensing tissue damage by myeloid C-Type lectin receptors. Curr Top Microbiol Immunol. 2020;429:117\u201345.","journal-title":"Curr Top Microbiol Immunol"},{"key":"738_CR16","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1016\/j.csbj.2022.10.019","volume":"20","author":"S Fischer","year":"2022","unstructured":"Fischer S, et al. From structure to function - Ligand recognition by myeloid C-type lectin receptors. Comput Struct Biotechnol J. 2022;20:5790\u2013812.","journal-title":"Comput Struct Biotechnol J"},{"key":"738_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fimmu.2020.00251","volume":"11","author":"M Drouin","year":"2020","unstructured":"Drouin M, Saenz J, Chiffoleau E. C-Type Lectin-Like receptors: Head or tail in cell death immunity. Front Immunol. 2020;11:251.","journal-title":"Front Immunol"},{"issue":"3","key":"738_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.immuni.2014.03.001","volume":"40","author":"S Yamasaki","year":"2014","unstructured":"Yamasaki S. Clec12a: quieting the dead. Immunity. 2014;40(3):309\u201311.","journal-title":"Immunity"},{"issue":"24","key":"738_CR19","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1111\/j.1742-4658.2005.05031.x","volume":"272","author":"AN Zelensky","year":"2005","unstructured":"Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. Febs j. 2005;272(24):6179\u2013217.","journal-title":"Febs j"},{"issue":"1","key":"738_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.celrep.2019.06.015","volume":"28","author":"MK Raulf","year":"2019","unstructured":"Raulf MK, et al. The C-type lectin receptor CLEC12A recognizes Plasmodial Hemozoin and contributes to cerebral Malaria Development. Cell Rep. 2019;28(1):30\u2013e385.","journal-title":"Cell Rep"},{"issue":"4","key":"738_CR21","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/ar4250","volume":"15","author":"V Gagn\u00e9","year":"2013","unstructured":"Gagn\u00e9 V, et al. Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications. Arthritis Res Ther. 2013;15(4):R73.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"738_CR22","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.4049\/jimmunol.1600011","volume":"197","author":"TJ Hutten","year":"2016","unstructured":"Hutten TJ, et al. CLEC12A-Mediated Antigen Uptake and Cross-presentation by Human dendritic cell subsets efficiently boost tumor-reactive T cell responses. J Immunol. 2016;197(7):2715\u201325.","journal-title":"J Immunol"},{"issue":"22","key":"738_CR23","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443\u201350.","journal-title":"Cancer Res"},{"issue":"1","key":"738_CR24","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1111\/bjh.17122","volume":"192","author":"H Matsuo","year":"2021","unstructured":"Matsuo H, et al. Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression. Br J Haematol. 2021;192(1):e7\u201311.","journal-title":"Br J Haematol"},{"issue":"4","key":"738_CR25","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/jcmm.13519","volume":"22","author":"M Bill","year":"2018","unstructured":"Bill M, et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J Cell Mol Med. 2018;22(4):2311\u20138.","journal-title":"J Cell Mol Med"},{"issue":"36","key":"738_CR26","doi-asserted-by":"publisher","first-page":"57811","DOI":"10.18632\/oncotarget.11063","volume":"7","author":"NH Darwish","year":"2016","unstructured":"Darwish NH, et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016;7(36):57811\u201320.","journal-title":"Oncotarget"},{"issue":"1","key":"738_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cyto.b.20614","volume":"82","author":"H Larsen","year":"2012","unstructured":"Larsen H, et al. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom. 2012;82(1):3\u20138.","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"738_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000510504","volume":"144","author":"LL Herborg","year":"2021","unstructured":"Herborg LL, et al. Antigen expression varies significantly between Molecular subgroups of Acute myeloid leukemia patients: clinical applicability is hampered by establishment of relevant Cutoffs. Acta Haematol. 2021;144(3):275\u201384.","journal-title":"Acta Haematol"},{"key":"738_CR29","doi-asserted-by":"publisher","first-page":"p6643948","DOI":"10.1155\/2021\/6643948","volume":"2021","author":"J Wang","year":"2021","unstructured":"Wang J, et al. C-Type Lectin-Like Molecule-1 as a biomarker for diagnosis and prognosis in Acute myeloid leukemia: a preliminary study. Biomed Res Int. 2021;2021:p6643948.","journal-title":"Biomed Res Int"},{"issue":"4","key":"738_CR30","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/hon.2352","volume":"35","author":"DS Eissa","year":"2017","unstructured":"Eissa DS, Kandeel EZ, Ghareeb M. Human myeloid inhibitory C-lectin: a highly specific and stable acute myeloid leukemia marker. Hematol Oncol. 2017;35(4):814\u201320.","journal-title":"Hematol Oncol"},{"key":"738_CR31","doi-asserted-by":"crossref","unstructured":"Hamed GM, Abdel MF, Fattah. Value of human CLEC12A expression in acute myeloid leukemia. Egypt J Haematol. 2016;41(4):161\u20137.","DOI":"10.4103\/1110-1067.198648"},{"issue":"9","key":"738_CR32","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1080\/10428194.2022.2064986","volume":"63","author":"Q Li","year":"2022","unstructured":"Li Q, et al. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia. Leuk Lymphoma. 2022;63(9):2136\u201348.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"738_CR33","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110(7):2659\u201366.","journal-title":"Blood"},{"issue":"8","key":"738_CR34","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","volume":"21","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, et al. Aberrant marker expression patterns on the CD34\u2009+\u2009CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21(8):1700\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"738_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41375-023-01811-5","volume":"37","author":"MF van Spronsen","year":"2023","unstructured":"van Spronsen MF, et al. Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. Leukemia. 2023;37(3):680\u201390.","journal-title":"Leukemia"},{"issue":"3","key":"738_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.14270","volume":"175","author":"M Toft-Petersen","year":"2016","unstructured":"Toft-Petersen M, et al. Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. Br J Haematol. 2016;175(3):393\u2013401.","journal-title":"Br J Haematol"},{"issue":"5","key":"738_CR37","doi-asserted-by":"publisher","first-page":"e0197823","DOI":"10.1371\/journal.pone.0197823","volume":"13","author":"BN Ostendorf","year":"2018","unstructured":"Ostendorf BN, et al. Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes. PLoS ONE. 2018;13(5):e0197823.","journal-title":"PLoS ONE"},{"issue":"3","key":"738_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ijlh.12787","volume":"40","author":"LL Herborg","year":"2018","unstructured":"Herborg LL, et al. Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: the utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. Int J Lab Hematol. 2018;40(3):320\u20135.","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"738_CR39","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.3324\/haematol.2018.214353","volume":"104","author":"D Schinnerl","year":"2019","unstructured":"Schinnerl D, et al. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica. 2019;104(8):e352\u20135.","journal-title":"Haematologica"},{"issue":"10","key":"738_CR40","doi-asserted-by":"publisher","first-page":"300060523120384","DOI":"10.1177\/03000605231203842","volume":"51","author":"H Shakah","year":"2023","unstructured":"Shakah H, et al. Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia. J Int Med Res. 2023;51(10):3000605231203842.","journal-title":"J Int Med Res"},{"issue":"20","key":"738_CR41","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1089\/scd.2016.0310","volume":"26","author":"YY Wang","year":"2017","unstructured":"Wang YY, et al. Low CLL-1 expression is a novel adverse predictor in 123 patients with De Novo CD34(+) Acute myeloid leukemia. Stem Cells Dev. 2017;26(20):1460\u20137.","journal-title":"Stem Cells Dev"},{"issue":"7","key":"738_CR42","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/leu.2017.113","volume":"31","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS, et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31(7):1482\u201390.","journal-title":"Leukemia"},{"key":"738_CR43","doi-asserted-by":"crossref","unstructured":"Mosna F, Capelli D, Gottardi M. Minimal residual disease in Acute myeloid leukemia: still a work in Progress? J Clin Med, 2017. 6(6).","DOI":"10.3390\/jcm6060057"},{"issue":"7","key":"738_CR44","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, et al. Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30(7):1456\u201364.","journal-title":"Leukemia"},{"issue":"2","key":"738_CR45","doi-asserted-by":"publisher","first-page":"101468","DOI":"10.1016\/j.beha.2023.101468","volume":"36","author":"ZC Wong","year":"2023","unstructured":"Wong ZC, Dillon LW, Hourigan CS. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia. Best Pract Res Clin Haematol. 2023;36(2):101468.","journal-title":"Best Pract Res Clin Haematol"},{"key":"738_CR46","doi-asserted-by":"publisher","first-page":"106477","DOI":"10.1016\/j.leukres.2020.106477","volume":"99","author":"B Yanagisawa","year":"2020","unstructured":"Yanagisawa B, et al. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Leuk Res. 2020;99:106477.","journal-title":"Leuk Res"},{"issue":"8","key":"738_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(8):66.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"738_CR48","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"738_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0453-8","volume":"10","author":"A Im","year":"2017","unstructured":"Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol. 2017;10:1\u201310.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"738_CR50","doi-asserted-by":"publisher","first-page":"pra179","DOI":"10.1126\/scitranslmed.3000349","volume":"2","author":"Y Saito","year":"2010","unstructured":"Saito Y, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):pra179\u2013ra179.","journal-title":"Sci Transl Med"},{"issue":"8","key":"738_CR51","doi-asserted-by":"publisher","first-page":"e0135945","DOI":"10.1371\/journal.pone.0135945","volume":"10","author":"KH Harrington","year":"2015","unstructured":"Harrington KH, et al. The broad anti-AML activity of the CD33\/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk. PLoS ONE. 2015;10(8):e0135945.","journal-title":"PLoS ONE"},{"issue":"10","key":"738_CR52","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin L, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167\u201374.","journal-title":"Nat Med"},{"issue":"2","key":"738_CR53","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"issue":"1","key":"738_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","volume":"5","author":"L Jin","year":"2009","unstructured":"Jin L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor \u03b1 chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31\u201342.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"738_CR55","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708\u201317.","journal-title":"Cell Stem Cell"},{"issue":"18","key":"738_CR56","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"738_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4252\/wjsc.v6.i4.473","volume":"6","author":"J Zhou","year":"2014","unstructured":"Zhou J, Chng W-J. Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia. World J stem Cells. 2014;6(4):473.","journal-title":"World J stem Cells"},{"issue":"1","key":"738_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3324\/haematol.2009.009811","volume":"95","author":"X Zhao","year":"2010","unstructured":"Zhao X, et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica. 2010;95(1):71.","journal-title":"Haematologica"},{"issue":"4","key":"738_CR59","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discovery. 2024;23(4):301\u201319.","journal-title":"Nat Rev Drug Discovery"},{"key":"738_CR60","doi-asserted-by":"crossref","unstructured":"Hoseini SS et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer, 2021. 9(5).","DOI":"10.1136\/jitc-2021-002509"},{"key":"738_CR61","doi-asserted-by":"publisher","first-page":"899468","DOI":"10.3389\/fimmu.2022.899468","volume":"13","author":"E Kubicka","year":"2022","unstructured":"Kubicka E, et al. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. Front Immunol. 2022;13:899468.","journal-title":"Front Immunol"},{"key":"738_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","volume":"132","author":"F Ravandi","year":"2018","unstructured":"Ravandi F, et al. A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML). Blood. 2018;132:25.","journal-title":"Blood"},{"issue":"37","key":"738_CR63","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1002\/ange.201405353","volume":"126","author":"H Lu","year":"2014","unstructured":"Lu H, et al. Targeting human C-type lectin\u2010like molecule\u20101 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem. 2014;126(37):9999\u201310003.","journal-title":"Angew Chem"},{"issue":"7","key":"738_CR64","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","volume":"19","author":"PF van Loo","year":"2019","unstructured":"van Loo PF, et al. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019;19(7):721\u201333.","journal-title":"Expert Opin Biol Ther"},{"key":"738_CR65","unstructured":"Mascarenhas J, et al. Update from the ongoing phase I multinational study of MCLA-117, a bispecific CLEC12A x CD3 T-cell engager, in patients (pts) with acute myelogenous leukemia (AML). European Hematology Association; 2020."},{"key":"738_CR66","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3389\/fonc.2020.00446","volume":"10","author":"O Vafa","year":"2020","unstructured":"Vafa O, Trinklein ND. Perspective: designing T-cell engagers with better therapeutic windows. Front Oncol. 2020;10:446.","journal-title":"Front Oncol"},{"key":"738_CR67","doi-asserted-by":"crossref","unstructured":"Dang K et al. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer, 2021. 9(6).","DOI":"10.1136\/jitc-2021-002488"},{"issue":"5","key":"738_CR68","first-page":"609","volume":"129","author":"SR Leong","year":"2017","unstructured":"Leong SR, et al. An anti-CD3\/anti\u2013CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood J Am Soc Hematol. 2017;129(5):609\u201318.","journal-title":"Blood J Am Soc Hematol"},{"key":"738_CR69","doi-asserted-by":"crossref","unstructured":"Lee E et al. Asymmetric anti-CLL-1\u00d7 CD3 bispecific antibody, ABL602 2\u2009+\u20091, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release. J Immunother Cancer, 2023. 11(10).","DOI":"10.1136\/jitc-2023-007494"},{"issue":"14","key":"738_CR70","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","volume":"22","author":"DA Vallera","year":"2016","unstructured":"Vallera DA, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33\u2009+\u2009targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res. 2016;22(14):3440\u201350.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"738_CR71","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","volume":"35","author":"US Arvindam","year":"2021","unstructured":"Arvindam US, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2021;35(6):1586\u201396.","journal-title":"Leukemia"},{"issue":"14","key":"738_CR72","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","volume":"2","author":"Y-P Jiang","year":"2018","unstructured":"Jiang Y-P, et al. CLT030, a leukemic stem cell\u2013targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018;2(14):1738\u201349.","journal-title":"Blood Adv"},{"issue":"6","key":"738_CR73","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/13543784.2011.573477","volume":"20","author":"JA Hartley","year":"2011","unstructured":"Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs. 2011;20(6):733\u201344.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"738_CR74","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","volume":"25","author":"B Zheng","year":"2019","unstructured":"Zheng B, et al. An anti\u2013CLL-1 antibody\u2013drug conjugate for the treatment of acute myeloid leukemia. Clin Cancer Res. 2019;25(4):1358\u201368.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"738_CR75","doi-asserted-by":"publisher","first-page":"E175","DOI":"10.1002\/ajh.26136","volume":"96","author":"N Daver","year":"2021","unstructured":"Daver N, et al. A phase I dose-escalation study of DCLL9718S, an antibody\u2010drug conjugate targeting C\u2010type lectin\u2010like molecule\u20101 (CLL\u20101) in patients with acute myeloid leukemia. Am J Hematol. 2021;96(5):E175\u20139.","journal-title":"Am J Hematol"},{"issue":"1","key":"738_CR76","first-page":"1","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou F. Efficacy of bone marrow transplantation in treating acute myeloid leukemia: a systematic review and meta-analysis. Am J Translational Res. 2023;15(1):1.","journal-title":"Am J Translational Res"},{"issue":"26","key":"738_CR77","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"738_CR78","first-page":"11","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood J Am Soc Hematol. 2021;138(1):11\u201322.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"738_CR79","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64\u201374.","journal-title":"Leukemia"},{"issue":"11","key":"738_CR80","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3390\/ijms18112259","volume":"18","author":"E Laborda","year":"2017","unstructured":"Laborda E, et al. Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 2017;18(11):2259.","journal-title":"Int J Mol Sci"},{"key":"738_CR81","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132:901.","journal-title":"Blood"},{"key":"738_CR82","doi-asserted-by":"publisher","first-page":"153303382211184","DOI":"10.1177\/15330338221118413","volume":"21","author":"D Xie","year":"2022","unstructured":"Xie D, et al. Relapse mechanism and treatment strategy after chimeric antigen receptor T-cell therapy in treating B-cell hematological malignancies. Technol Cancer Res Treat. 2022;21:15330338221118413.","journal-title":"Technol Cancer Res Treat"},{"key":"738_CR83","doi-asserted-by":"publisher","first-page":"101695","DOI":"10.1016\/j.tranon.2023.101695","volume":"34","author":"D Xie","year":"2023","unstructured":"Xie D, et al. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape. Translational Oncol. 2023;34:101695.","journal-title":"Translational Oncol"},{"issue":"13","key":"738_CR84","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27(13):3549\u201355.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"738_CR85","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88.","journal-title":"J Hematol Oncol"},{"key":"738_CR86","doi-asserted-by":"crossref","unstructured":"Geyer MB et al. CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia. Blood, 2024. 144: p. 2070.","DOI":"10.1182\/blood-2024-194162"},{"issue":"2","key":"738_CR87","first-page":"615","volume":"12","author":"Y-J Ma","year":"2022","unstructured":"Ma Y-J, et al. Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am J Cancer Res. 2022;12(2):615.","journal-title":"Am J Cancer Res"},{"key":"738_CR88","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1182\/blood-2024-206430","volume":"144","author":"AV Verghese","year":"2024","unstructured":"Verghese AV, et al. Prospective study of CLL1 and CD45RA as biomarkers of leukemic stem cells to predict therapeutic response in Acute myeloid leukemia. Blood. 2024;144:6105.","journal-title":"Blood"},{"issue":"8","key":"738_CR89","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/cam4.5916","volume":"12","author":"K Pei","year":"2023","unstructured":"Pei K, et al. Anti-CLL1\u2010based CAR T\u2010cells with 4\u20101\u2010BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia. Cancer Med. 2023;12(8):9655\u201361.","journal-title":"Cancer Med"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00738-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:19:03Z","timestamp":1739366343000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00738-6","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}